生物活性：Ropivacaine-d7 hydrochloride is a deuterium labeled Ropivacaine (hydrochloride) (HY-B0563B)[1]. Ropivacaine hydrochloride is a potent sodium channel blocker and blocks impulse conduction via reversible inhibition of sodium ion influx in nerve fibrese[2][3]. Ropivacaine is also an inhibitor of K2P (two-pore domain potassium channel) TREK-1 with an IC50 of 402.7 μM in COS-7 cell's membrane[4]. Ropivacaine is widely used for neuropathic pain management in vivo[2].
体外研究(In Vitro)：氢、碳和其他元素的稳定重同位素已被纳入药物分子中，主要作为药物开发过程中定量的示踪剂。氘化引起了人们的关注，因为它可能影响药物的药代动力学和代谢谱[1]。
瑞禧生物 has not independently confirmed the accuracy of these methods. They are for reference only.
Ropivacaine-d7 hydrochloride 相关抗体:
xCT Antibody (YA006)
xCT Antibody (YA652)
ATP1A1 Antibody
Alpha-ENaC Antibody
LGI1 Antibody (YA2885)
CRMP2 Antibody (YA3370)
SLC12A1 Antibody (YA1403)
CRMP1 Antibody (YA1941)
Cardiac Troponin C Antibody (YA2125)
CRMP5 Antibody (YA2497)
CRMP3 Antibody (YA2563)
Cardiac Troponin T Antibody (YA2719)
SAP97 Antibody (YA2731)
CRMP4 Antibody (YA2777)
Kir2.1 Antibody (YA2871)
分子量：317.91
Formula：C17H20D7ClN2O
CAS 号：1217667-10-1
非标记 CAS：84057-95-4
中文名称：盐酸罗哌卡因-d7
运输条件：Room temperature in continental US; may vary elsewhere.
储存方式：Please store the product under the recommended conditions in the Certificate of Analysis.
纯度 & 产品资料
Data Sheet (546 KB)
产品使用指南 (1538 KB)
参考文献
[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-246.
 [Content Brief]
[2]. Li TF, et al. Epidural sustained release ropivacaine prolongs anti-allodynia and anti-hyperalgesia in developing and established neuropathic pain. PLoS One. 2015 Jan 24;10(1):e0117321.
 [Content Brief]
[3]. Milan Patel, et al. Ropivacaine Inhibits Pressure-Induced Lung Endothelial Hyperpermeability in Models of Acute Hypertension. Life Sci. 2019 Apr 1;222:22-28.
 [Content Brief]
[4]. Dene Simpson, et al. Ropivacaine: a review of its use in regional anaesthesia and acute pain management. Drugs. 2005;65(18):2675-717.
 [Content Brief]
[5]. Hye Won Shin, et al. The inhibitory effects of bupivacaine, levobupivacaine, and ropivacaine on K2P (two-pore domain potassium) channel TREK-1. J Anesth. 2014 Feb;28(1):81-6.
 [Content Brief]